Literature DB >> 29651642

Thulium laser VapoResection of the prostate versus traditional transurethral resection of the prostate or transurethral plasmakinetic resection of prostate for benign prostatic obstruction: a systematic review and meta-analysis.

Zheng Deng1, Menghao Sun1, Yiping Zhu1, Jian Zhuo1, Fujun Zhao1, Shujie Xia2, Bangmin Han3, Thomas R W Herrmann4.   

Abstract

PURPOSE: To compare the efficacy and safety of thulium laser VapoResection of the prostate (ThuVaRP) versus standard traditional transurethral resection of the prostate (TURP) or plasmakinetic resection of prostate (PKRP) for benign prostatic obstruction.
METHODS: Systematic searches were performed in the Medline, EMBASE, the Cochrane Library, Web of Science, and CNKI in December 2017. The outcomes of demographic and clinical characteristics, perioperative variables, complications, and postoperative efficacy including International Prostate Symptom Score (IPSS), quality of life (QoL), maximum flow rate (Qmax), and postvoid residual (PVR) were assessed.
RESULTS: 16 studies were selected in the meta-analysis including nine randomized controlled trials (RCTs) and seven non-RCTs. Among of them, nine studies compared ThuVaRP with PKRP, while seven studies compared ThuVaRP with TURP. It seemed that ThuVaRP needed longer operation time than TURP (WMD = 6.41, 95% CI 1.38-11.44, p = 0.01) and PKRP (WMD = 10.15, 95% CI 5.20-15.10, p < 0.0001). ThuVaRP was associated with less serum hemoglobin decreased, catheterization time, and the length of hospital stay compared with TURP (WMD = - 0.58, 95% CI - 0.77 to 0.38, p < 0.00001; WMD = - 1.89, 95% CI - 2.67 to 1.11, p < 0.00001; WMD = - 2.25, 95% CI - 2.91 to 1.60, p < 0.00001) and PKRP (WMD = - 0.28, 95% CI - 0.46 to 0.10, p = 0.002; WMD = - 1.88, 95% CI - 2.87 to 0.89, p = 0.0002; WMD = - 2.08, 95% CI - 2.63 to 1.54, p<0.00001). According to our assessment, there was no significantly difference in postoperative efficacy.
CONCLUSIONS: The pooled data indicated that ThuVaRP had a nearly efficacy to TURP and PKRP based on IPSS, QoL, Qmax, and PVR. Although ThuVaRP was associated with longer operation time, it got distinct superiority on serum hemoglobin decreased, catheterization time, and hospital stay.

Entities:  

Keywords:  2-micron; Benign prostatic obstruction,; Plasmakinetic resection of prostate,; Safety and efficacy; Thulium laser VapoResection of the prostate,; Thulium laser,; Transurethral resection of the prostate,

Mesh:

Substances:

Year:  2018        PMID: 29651642     DOI: 10.1007/s00345-018-2287-6

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  30 in total

1.  Two-micron (thulium) laser resection of the prostate-tangerine technique: a new method for BPH treatment.

Authors:  Shu-Jie Xia
Journal:  Asian J Androl       Date:  2009-04-27       Impact factor: 3.285

2.  Systematic evaluation of a recently introduced 2-microm continuous-wave thulium laser for vaporesection of the prostate.

Authors:  Gunnar Wendt-Nordahl; Stephanie Huckele; Patrick Honeck; Peter Alken; Thomas Knoll; Maurice Stephan Michel; Axel Häcker
Journal:  J Endourol       Date:  2008-05       Impact factor: 2.942

3.  Long-term results of a randomized trial comparing holmium laser enucleation of the prostate and transurethral resection of the prostate: results at 7 years.

Authors:  Peter J Gilling; Liam C Wilson; Colleen J King; Andre M Westenberg; Christopher M Frampton; Mark R Fraundorfer
Journal:  BJU Int       Date:  2011-08-23       Impact factor: 5.588

Review 4.  Thulium: YAG 2 mum cw laser prostatectomy: where do we stand?

Authors:  T Bach; S J Xia; Y Yang; S Mattioli; G M Watson; A J Gross; T R W Herrmann
Journal:  World J Urol       Date:  2010-03-05       Impact factor: 4.226

Review 5.  Bipolar versus monopolar transurethral resection of the prostate: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Charalampos Mamoulakis; Dirk T Ubbink; Jean J M C H de la Rosette
Journal:  Eur Urol       Date:  2009-07-07       Impact factor: 20.096

6.  Long-term results of thulium laser resection of the prostate: a prospective study at multiple centers.

Authors:  Feng Sun; Bangmin Han; Di Cui; Fujun Zhao; Xiaowen Sun; Jian Zhuo; Yifeng Jing; Haitao Liu; Shujie Xia; Yong Yang; Guangheng Luo; Fengfu Guo
Journal:  World J Urol       Date:  2014-12-09       Impact factor: 4.226

Review 7.  Thulium Laser Resection Versus Plasmakinetic Resection of Prostates in the Treatment of Benign Prostate Hyperplasia: A Meta-Analysis.

Authors:  Chenming Zhao; Huan Yang; Zhiqiang Chen; Zhangqun Ye
Journal:  J Laparoendosc Adv Surg Tech A       Date:  2016-08-08       Impact factor: 1.878

8.  A randomized trial comparing thulium laser resection to standard transurethral resection of the prostate for symptomatic benign prostatic hyperplasia: four-year follow-up results.

Authors:  Di Cui; Feng Sun; Jian Zhuo; Xiaowen Sun; Bangmin Han; Fujun Zhao; Yifeng Jing; Jun Lu; Shujie Xia
Journal:  World J Urol       Date:  2013-08-03       Impact factor: 4.226

9.  Endoscopic vaporesection of the prostate using the continuous-wave 2-microm thulium laser: outcome and demonstration of the surgical technique.

Authors:  Roman Szlauer; Robert Götschl; Aria Razmaria; Ljiljana Paras; Nikolaus T Schmeller
Journal:  Eur Urol       Date:  2008-11-12       Impact factor: 20.096

10.  An Analytical Comparison of Short-term Effectiveness and Safety Between Thulium:YAG Laser Vaporesection of the Prostate and Bipolar Transurethral Resection of the Prostate in Patients With Benign Prostatic Hyperplasia.

Authors:  Joon Woo Kim; Yeon Joo Kim; Yoon Hyung Lee; Joon Beom Kwon; Sung Ryong Cho; Jae Soo Kim
Journal:  Korean J Urol       Date:  2014-01-15
View more
  5 in total

1.  Thulium laser transurethral vaporesection versus transurethral resection of the prostate for benign prostatic obstruction: the UNBLOCS RCT.

Authors:  Jo Worthington; J Athene Lane; Hilary Taylor; Grace Young; Sian M Noble; Paul Abrams; Aideen Ahern; Sara T Brookes; Nikki Cotterill; Lyndsey Johnson; Rafiyah Khan; Aida Moure Fernandez; Tobias Page; Satchi Swami; Hashim Hashim
Journal:  Health Technol Assess       Date:  2020-09       Impact factor: 4.014

Review 2.  Current Treatment for Benign Prostatic Hyperplasia.

Authors:  Arkadiusz Miernik; Christian Gratzke
Journal:  Dtsch Arztebl Int       Date:  2020-12-04       Impact factor: 5.594

3.  Thulium laser transurethral vaporesection of the prostate versus transurethral resection of the prostate for men with lower urinary tract symptoms or urinary retention (UNBLOCS): a randomised controlled trial.

Authors:  Hashim Hashim; Jo Worthington; Paul Abrams; Grace Young; Hilary Taylor; Sian M Noble; Sara T Brookes; Nikki Cotterill; Tobias Page; K Satchi Swami; J Athene Lane
Journal:  Lancet       Date:  2020-07-04       Impact factor: 79.321

4.  Comparison of Multipulse Laser Vaporesection versus Plasmakinetic Resection for Treatment of Benign Prostate Obstruction.

Authors:  Fu-Shun Hsu; Chen-Wei Chou; Hong-Chiang Chang; Yuan-Po Tu; Shing-Jia Sha; Huang-Hsin Chung; Kuo-How Huang
Journal:  Sci Rep       Date:  2019-04-23       Impact factor: 4.379

5.  Thulium Laser Vapoenucleation of the Prostate (ThuVEP) in Men at High Cardiovascular Risk and on Antithrombotic Therapy: A Single-Center Experience.

Authors:  Daniele Castellani; Mirko Di Rosa; Luca Gasparri; Michele Pucci; Marco Dellabella
Journal:  J Clin Med       Date:  2020-03-27       Impact factor: 4.241

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.